Key Points
- Maze Therapeutics CEO Jason Coloma sold 25,582 shares on May 26 at an average price of $26.02, totaling about $665,644. The sale was made under a pre-arranged Rule 10b5-1 plan, and his direct stake fell by 6.79%.
- The stock closed around $26.05, well below its 50-day and 200-day moving averages, while the company’s market cap stood at about $1.44 billion. Maze also has a notably strong liquidity position, with a quick ratio and current ratio of 17.88.
- Maze Therapeutics recently reported a quarterly loss of $0.45 per share, slightly worse than analyst expectations, though revenue came in at $20.0 million. Despite the miss, Wall Street remains generally bullish, with a consensus Buy rating and an average price target of $66.00.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CEO Jason Coloma sold 6,982 shares of the firm's stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $26.00, for a total transaction of $181,532.00. Following the completion of the sale, the chief executive officer owned 28,523 shares in the company, valued at $741,598. This represents a 19.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Maze Therapeutics Trading Down 1.1%
Shares of MAZE stock opened at $26.05 on Thursday. Maze Therapeutics, Inc. has a 12-month low of $9.73 and a 12-month high of $53.65. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. The firm's 50 day moving average is $29.69 and its 200 day moving average is $37.61. The stock has a market capitalization of $1.44 billion, a P/E ratio of -10.30 and a beta of 2.50.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. Research analysts expect that Maze Therapeutics, Inc. will post -2.74 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on the stock. Wedbush raised their price objective on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an "outperform" rating in a research report on Monday, March 16th. BTIG Research restated a "buy" rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Mizuho upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research report on Wednesday, March 11th. HC Wainwright raised their price objective on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, March 25th. Finally, Wall Street Zen upgraded shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $66.00.
Read Our Latest Stock Analysis on Maze Therapeutics
Institutional Trading of Maze Therapeutics
Several hedge funds have recently bought and sold shares of MAZE. Janus Henderson Group PLC lifted its stake in Maze Therapeutics by 318.0% in the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company's stock worth $130,197,000 after purchasing an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. lifted its stake in Maze Therapeutics by 218.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company's stock worth $34,615,000 after purchasing an additional 915,342 shares in the last quarter. Marshall Wace LLP lifted its stake in Maze Therapeutics by 3,868.5% in the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company's stock worth $20,166,000 after purchasing an additional 758,104 shares in the last quarter. Caligan Partners LP purchased a new stake in Maze Therapeutics in the 4th quarter worth $22,794,000. Finally, ArrowMark Colorado Holdings LLC purchased a new stake in Maze Therapeutics in the 3rd quarter worth $14,135,000.
Maze Therapeutics Company Profile
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
